Alyeska Investment Group
ALT icon

Alyeska Investment Group’s Altimmune ALT Stock Holding History

Alyeska Investment Group’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,644,600
Closed -$8.15M – 661
2026
Q1 		$8.15M Buy
+2,644,600
New +$11.2M 0.02% 423

Other funds holding ALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alyeska Investment Group's ALT Position: Q2 2026 in Review

Alyeska Investment Group sold out of Altimmune (ALT) in Q2 2026, closing a stake of 2,644,600 shares — an estimated $8.15M sold.

Alyeska Investment Group first reported a position in ALT in Q1 2026 and held it in 1 quarter. The position peaked at $8.15M in Q1 2026. 210 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

  • Alyeska Investment Group reported no remaining Altimmune position as of Q2 2026 after selling out during the quarter.
  • Alyeska Investment Group sold 2,644,600 Altimmune shares in Q2 2026, an estimated $8.15M.
  • Alyeska Investment Group first reported a position in Altimmune in Q1 2026 and held it in 1 quarter.
  • Alyeska Investment Group's Altimmune position peaked at $8.15M in Q1 2026.
  • 210 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.